Futura Medical plc announced that it has signed a licensing agreement with the UK subsidiary of STADA Arzneimittel AG, the international healthcare group, for the commercialisation of TPR100, the company's novel diclofenac gel for pain relief. The licensing agreement was signed with Huddersfield-based Thornton & Ross Ltd, which was acquired by STADA three years ago. Under the terms of the agreement, Thornton & Ross will conduct the manufacturing scale-up of TPR100 and hold rights to manufacture, market and distribute the product in the UK for the lifetime of the product's patents, which run to at least 2028 in the UK. Futura will receive an upfront payment and milestone payments up to a certain limit along with royalties on product sales. Further financial or other details are not being disclosed.